FDA Inspection 1297366 — Andrew Spencer
The FDA completed an inspection of Andrew Spencer on November 28, 2025 in Melbourne. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 28, 2025
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Melbourne (Australia)
Additional Details
Clinical Investigator (CI)